Brief: Hookipa Announces Strategic Collaboration And License Agreement With Roche To Develop Novel Arenaviral Immunotherapy For Kras-Mutated Cancers

Hookipa Pharma

20/10/2022 12:53

Oct 20 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA ANNOUNCES STRATEGIC COLLABORATION AND LICENSE
AGREEMENT
WITH ROCHE TO DEVELOP NOVEL ARENAVIRAL IMMUNOTHERAPY FOR
KRAS-MUTATED CANCERS
    * HOOKIPA PHARMA INC- ROCHE TO RECEIVE LICENSE FOR HOOKIPA'S
HB-700 PROGRAM AND OPTION TO LICENSE A SECOND UNDISCLOSED NOVEL
ARENAVIRAL IMMUNOTHERAPY
    * HOOKIPA PHARMA INC- HOOKIPA ELIGIBLE FOR RESEARCH,
DEVELOPMENT &
COMMERCIALIZATION MILESTONE-BASED PAYMENTS FOR HB-700
    * HOOKIPA PHARMA INC- HOOKIPA ALSO ELIGIBLE FOR ADDITIONAL
PRODUCT
CANDIDATE TOTALING UP TO ABOUT $930 MILLION
    * HOOKIPA PHARMA INC- TO GET $25 MILLION IN UPFRONT CASH,
POTENTIAL FUTURE SUCCESS-BASED MILESTONE PAYMENTS UP TO ABOUT
$930 MILLION

Source text for Eikon:  ID:nGNX7rTwv8 
Further company coverage:  HOOK.O 
 ((Reuters.Briefs@thomsonreuters.com;;))